ADA 2017: Outlook For New Longer Acting Insulins Amid US Pricing Sensitivity
The high cost of basal insulins in the US has drawn a fair amount of scrutiny recently, placing increased pressure on new longer acting insulins to demonstrate superior cost-efficacy compared to standard of care Lantus to gain preferential formulary placement. This has become significantly more difficult with the US launch of Lilly's biosimilar, Basaglar.
You may also be interested in...
Lars Fruergaard Jørgensen, Novo Nordisk's CEO, says the group's pledge on price transparency, goals for improved outcomes and experimental use of digital health are commercially linked.
While other companies have promised not to raise their drug prices beyond 10%, Sanofi is using the rate of medical inflation (expected to be 5.4% in 2017) in setting its annual list price hikes. Company retains option to increase prices beyond benchmark.
A robust first quarter allowed the Danish diabetes fighter to tighten its guidance - but things are likely to get bumpier for the troubled group as the year progresses.